Latest news with #HistoSonics
Yahoo
4 days ago
- Business
- Yahoo
HistoSonics announces acquisition by investor consortium for $2.25bn
HistoSonics has announced a substantial management-led majority stake acquisition by a consortium of investors, including public and private entities, with a transaction that values the company at around $2.25bn. This strategic move is set to expedite the company's growth and facilitate the expansion of the Edison Histotripsy System into new clinical indications and markets, according to a company release. The company will continue under the leadership of CEO and president Mike Blue, alongside his executive team. Blue will also become the chairman of the board on the closing of the transaction. Blue said: 'This new group of partners backs category-defining companies that transform entire industries. 'Their support gives us the firepower to accelerate our momentum, expand into new clinical indications, and reach even more patients around the world who urgently need our breakthrough therapy.' The deal enables HistoSonics to broaden its therapeutic reach, targeting not only liver tumours but also pancreas, prostate, and kidney conditions. Established in 2009, the company envisions a future where histotripsy can be applied to a wide array of clinical applications, treating both benign and malignant conditions. The Edison system has reportedly been used to treat over 2,000 individuals at more than 50 US medical centres so far, with plans to install another 50 systems by the year's end. The system is intended for the non-invasive destruction of liver tumours, including unresectable liver tumours, leveraging a non-thermal, mechanical process of focused ultrasound. In October 2023, the company secured marketing authorisation from the US Food and Drug Administration (FDA) for its Edison histotripsy platform. The company is backed by preclinical and clinical research across several organ systems. HistoSonics is actively enrolling subjects in clinical trials for kidney, liver, and pancreas tumours, with further trials slated to begin shortly. The investment syndicate features Bezos Expeditions, K5 Global, and Wellington Management, along with Alpha JWC Ventures and other existing investors such as Venture Investors Health Fund and Alpha Wave Ventures. Lumira Ventures and Early Stage Partners are also part of the investor group. Financial advisory services for HistoSonics were provided by Citi, with Fox Rothschild acting as legal advisers. The investment syndicate was advised by Morgan Stanley & Co and Cooley, with assistance from Orrick while Wilson Sonsini Goodrich & Rosati advised HistoSonics' major existing shareholders. "HistoSonics announces acquisition by investor consortium for $2.25bn" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
HistoSonics宣布被頂尖投資人聯盟以22.5億美元收購
HistoSonics Edison組織摧毀術系統影片（影片來源：HistoSonics） HistoSonics非侵入性Edison組織摧毀術系統（圖片來源：HistoSonics） 圖片來源：HistoSonics 此次收購將加快公司突破性Edison®組織摧毀術平台及非侵入性腫瘤療法的全球擴張 明尼亞波里斯, August 08, 2025--(BUSINESS WIRE)--(美國商業資訊)--Edison®組織摧毀術系統及新型組織摧毀術治療平台的研發企業HistoSonics今日宣布，由一批全球知名的私人和公共投資人組成的聯盟將以管理層主導的方式收購其多數股權，投資方包括K5 Global、Bezos Expeditions、Wellington Management以及其他新投資人和現有投資人。此次交易對HistoSonics的估值約為22.5億美元，將協助公司加快Edison系統在新臨床適應症及全球市場的成長。 HistoSonics將繼續由總裁兼執行長Mike Blue及其管理團隊領導。交易完成後，Blue先生還將擔任董事長一職。 Blue先生表示：「身為一家公司，我們始終專注於速度、規模，以及為病患提供比現有方案更優選擇的迫切使命。這批新合作夥伴支援那些定義品類、變革整個產業的企業。他們的支援將為我們注入動力，加大發展動力，擴大至新的臨床適應症，嘉惠全球更多亟需我們突破性療法的病患。」 HistoSonics計畫在初始聚焦的肝腫瘤之外，將業務擴充至腎、胰腺和攝護腺腫瘤適應症，其長期願景是讓組織摧毀術應用於全身多種臨床場景，同時治療良性和惡性疾病。 K5 Global共同創辦人兼管理合夥人Bryan Baum表示：「HistoSonics的亮點不僅在於技術，更在於團隊將突破性成果轉化為實際臨床進展的速度和清晰度。醫院持續訂購系統，病患需求激增，臨床結果不言自明。我們選擇與HistoSonics合作，是因為這是罕見的科學、執行力與商機完美契合的時刻，我們將協助其療法嘉惠全球每一家醫院。」 HistoSonics成立于2009年，於2023年10月獲得美國食品藥物管理局(FDA)的De Novo核准，它採用非侵入性聚焦超音波能量，在亞細胞層面以機械方式摧毀並液化目標群組織和腫瘤，且沒有傳統手術的侵入性或毒性。 截至目前，全美50多家頂尖醫療中心已使用Edison系統治療超過2000名病患，預計年底前還將安裝50套系統。憑藉在肝、腎、胰腺、攝護腺等多個器官系統的廣泛臨床前和臨床研究，公司目前正在招募肝腫瘤、腎腫瘤（HOPE4KIDNEY試驗，NCT05820087）和胰腺腫瘤（GANNON試驗，NCT06282809）的臨床試驗病患，並計畫在近期啟動其他試驗。 參與此次交易的其他投資方包括頂尖全球投資機構，如Alpha JWC Ventures，以及現有投資人Alpha Wave Ventures、Venture Investors Health Fund、Lumira Ventures、Hatteras Venture Partners、Early Stage Partners、Amzak Health、HealthQuest Capital、Yonjin Venture、威斯康辛州投資委員會、密西根州退休系統，以及透過其企業創投部門Johnson & Johnson - JJDC, Inc. (JJDC)參與其中的Johnson & Johnson等。 Citi擔任HistoSonics的財務顧問，Fox Rothschild擔任其法律顧問。Morgan Stanley & Co. LLC擔任投資聯盟的財務顧問，Cooley在Orrick的協助下擔任其法律顧問。Wilson Sonsini Goodrich & Rosati擔任HistoSonics現有主要股東的法律顧問。 HistoSonics 公司概覽 HistoSonics是一家私人醫療器材公司，利用組織摧毀術開發非侵入性平台和專有聲束療法。組織摧毀術是一種利用聚焦超音波以機械方式破壞和液化多餘組織和腫瘤的新型作用機制。該公司目前專注於在美國和部分全球市場將其用於肝臟治療的Edison系統商業化，同時將組織摧毀術的應用擴充到腎臟、胰腺、攝護腺等其他器官。HistoSonics在密西根州安娜堡和明尼蘇達州明尼亞波里斯設有辦事處。如欲瞭解有關Edison組織摧毀術系統的更多資訊，請造訪： 免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。 請前往 瀏覽源版本: Contacts 媒體連絡人： Josh King 行銷副總裁 608.332.8124 Kimberly Ha KKH Advisors 917-291-5744
Business Upturn
5 days ago
- Business
- Business Upturn
HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors
Business Wire India HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced a management-led majority stake acquisition by a syndicate of globally recognized private and public investors, including K5 Global, Bezos Expeditions, Wellington Management and other new and existing investors. The transaction values HistoSonics at approximately $2.25 billion and positions the company for accelerated growth of the Edison System across new clinical indications and global markets. This press release features multimedia. View the full release here: HistoSonics Non-Invasive Edison Histotripsy System Image credit: HistoSonics HistoSonics will continue to be led by President and Chief Executive Officer, Mike Blue, and his executive team. Mr. Blue will also assume the role of Chairman of the Board upon closing. 'Our relentless focus as a company has been speed, scale, and the urgency to offer patients a better option than any they have today,' said Mr. Blue. 'This new group of partners backs category-defining companies that transform entire industries. Their support gives us the firepower to accelerate our momentum, expand into new clinical indications, and reach even more patients around the world who urgently need our breakthrough therapy.' HistoSonics plans to expand beyond its initial focus on liver tumors to kidney, pancreas, and prostate indications, with a long-term vision of histotripsy being used across a wide range of clinical applications throughout the body, treating both benign and malignant conditions. 'What stood out with HistoSonics wasn't just the technology, it was the speed and clarity with which the team turned a breakthrough into real clinical traction,' said Bryan Baum, Co-Founder and Managing Partner, K5 Global. 'Hospitals are continuing to order systems, patient demand is surging, and the clinical results speak for themselves. We partnered with HistoSonics because this is one of those rare moments where the science, the execution, and the opportunity all align, and we are here to ensure it reaches every hospital in the world.' HistoSonics, founded in 2009, received FDA De Novo clearance in October 2023 and uses non-invasive focused ultrasound energy to mechanically destroy and liquify targeted tissue and tumors at a sub-cellular level and without the invasiveness or toxicity of traditional procedures. To date, over 2,000 patients have been treated by the Edison system at over 50 leading U.S. medical centers, with another 50 planned system installations by year-end. Supported by extensive preclinical and clinical research across multiple organ systems, including liver, kidney, pancreas, prostate and others, the company is currently enrolling patients in clinical trials for liver tumors, kidney tumors (HOPE4KIDNEY Trial NCT05820087) and pancreas tumors (GANNON Trial NCT06282809), with plans to start others in the near future. Additional participants in the transaction include top‑tier global investment firms, including Alpha JWC Ventures, alongside existing investors Alpha Wave Ventures, Venture Investors Health Fund, Lumira Ventures, Hatteras Venture Partners, Early Stage Partners, Amzak Health, HealthQuest Capital, Yonjin Venture, the State of Wisconsin Investment Board, the State of Michigan Retirement System, Johnson & Johnson through its corporate venture capital organization, Johnson & Johnson – JJDC, Inc. (JJDC), and others. Citi served as financial advisor and Fox Rothschild served as legal advisor to HistoSonics. Morgan Stanley & Co. LLC served as financial advisor and Cooley, with assistance from Orrick, served as legal advisors to the investment syndicate. Wilson Sonsini Goodrich & Rosati served as legal advisor to Histosonics' existing major shareholders. About HistoSonics HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, and others. HistoSonics has offices in Ann Arbor, MI and Minneapolis, MN. For more information on the Edison Histotripsy System please visit: For patient-related information please visit: View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
Business Wire
5 days ago
- Business
- Business Wire
HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors
MINNEAPOLIS--(BUSINESS WIRE)-- HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced a management-led majority stake acquisition by a syndicate of globally recognized private and public investors, including K5 Global, Bezos Expeditions, Wellington Management and other new and existing investors. The transaction values HistoSonics at approximately $2.25 billion and positions the company for accelerated growth of the Edison System across new clinical indications and global markets. HistoSonics will continue to be led by President and Chief Executive Officer, Mike Blue, and his executive team. Mr. Blue will also assume the role of Chairman of the Board upon closing. 'Our relentless focus as a company has been speed, scale, and the urgency to offer patients a better option than any they have today,' said Mr. Blue. 'This new group of partners backs category-defining companies that transform entire industries. Their support gives us the firepower to accelerate our momentum, expand into new clinical indications, and reach even more patients around the world who urgently need our breakthrough therapy.' HistoSonics plans to expand beyond its initial focus on liver tumors to kidney, pancreas, and prostate indications, with a long-term vision of histotripsy being used across a wide range of clinical applications throughout the body, treating both benign and malignant conditions. 'What stood out with HistoSonics wasn't just the technology, it was the speed and clarity with which the team turned a breakthrough into real clinical traction,' said Bryan Baum, Co-Founder and Managing Partner, K5 Global. 'Hospitals are continuing to order systems, patient demand is surging, and the clinical results speak for themselves. We partnered with HistoSonics because this is one of those rare moments where the science, the execution, and the opportunity all align, and we are here to ensure it reaches every hospital in the world.' HistoSonics, founded in 2009, received FDA De Novo clearance in October 2023 and uses non-invasive focused ultrasound energy to mechanically destroy and liquify targeted tissue and tumors at a sub-cellular level and without the invasiveness or toxicity of traditional procedures. To date, over 2,000 patients have been treated by the Edison system at over 50 leading U.S. medical centers, with another 50 planned system installations by year-end. Supported by extensive preclinical and clinical research across multiple organ systems, including liver, kidney, pancreas, prostate and others, the company is currently enrolling patients in clinical trials for liver tumors, kidney tumors (HOPE4KIDNEY Trial NCT05820087) and pancreas tumors (GANNON Trial NCT06282809), with plans to start others in the near future. Additional participants in the transaction include top‑tier global investment firms, including Alpha JWC Ventures, alongside existing investors Alpha Wave Ventures, Venture Investors Health Fund, Lumira Ventures, Hatteras Venture Partners, Early Stage Partners, Amzak Health, HealthQuest Capital, Yonjin Venture, the State of Wisconsin Investment Board, the State of Michigan Retirement System, Johnson & Johnson through its corporate venture capital organization, Johnson & Johnson - JJDC, Inc. (JJDC), and others. Citi served as financial advisor and Fox Rothschild served as legal advisor to HistoSonics. Morgan Stanley & Co. LLC served as financial advisor and Cooley, with assistance from Orrick, served as legal advisors to the investment syndicate. Wilson Sonsini Goodrich & Rosati served as legal advisor to Histosonics' existing major shareholders. About HistoSonics HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, and others. HistoSonics has offices in Ann Arbor, MI and Minneapolis, MN. For more information on the Edison Histotripsy System please visit: For patient-related information please visit:
Wall Street Journal
5 days ago
- Business
- Wall Street Journal
Liver Tumor Therapy Company HistoSonics Valued at $2.25 Billion in Sale
Investors have struck a deal to buy a majority stake in HistoSonics, valuing the company whose noninvasive therapy for liver tumors shows promise in other diseases at $2.25 billion. An investor group acquired two-thirds of Plymouth, Minn.-based HistoSonics, which uses focused ultrasound to mechanically destroy and liquefy tumors.
